Nachrichten zur Jazz Pharmaceuticals plc Aktie

10 Biggest Price Target Changes For Wednesday

Piper Jaffray lowered Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) price target from $205 to $142. Jazz Pharmaceuticals shares closed at…

Is Jazz Pharmaceuticals (JAZZ) a Profitable Value Stock-

Jazz Pharmaceuticals (JAZZ) stock may be a good choice for value-oriented investors right now from multiple angles....…

Jazz Pharmaceuticals buys biotechnology firm Cavion for £259m

As per terms of the deal, the former Cavion shareholders have secured an upfront payment of $52.5m (£43.5m). They are…

Jazz Pharmaceuticals Announces Acquisition of Cavion, Inc.

DUBLIN , Aug. 12, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the…

Jazz Pharma (JAZZ) Q2 Earnings and Sales Beat Estimates

Jazz Pharmaceuticals (JAZZ) reports encouraging second-quarter 2019 earnings and revenues and raises its sales guidance for 2019....…

Jazz Pharmaceuticals Sings a Sweet Tune in Q2

The drugmaker delivered revenue and earnings beats thanks to continued momentum for sleep disorder drug Xyrem....…

Jazz Pharmaceuticals (JAZZ) Q2 2019 Earnings Call Transcript

JAZZ earnings call for the period ending June 30, 2019....…

Jazz Pharmaceuticals plc (JAZZ) CEO Bruce Cozadd on Q2 2019 Results - Earnings Call Transcript

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Jazz Pharmaceuticals (JAZZ) Beats Q2 Earnings and Revenue Estimates

Jazz (JAZZ) delivered earnings and revenue surprises of 13.45% and 5.08%, respectively, for the quarter ended June 2019. Do the…

Jazz Pharmaceuticals plc 2019 Q2 - Results - Earnings Call Slides

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Jazz Pharmaceuticals Announces Second Quarter 2019 Financial Results

DUBLIN , Aug. 6, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial…

Jazz Pharmaceuticals Advances Recombinant Crisantaspase Development Program

DUBLIN , Aug. 6, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that…

Jazz (Pharmaceuticals) Has Pizzazz With Quant Upgrade and Bullish Charts

Um den gesamten Artikel unter realmoney.thestreet.com zu lesen, klicken Sie bitte auf die Überschrift...…

Jazz Pharmaceuticals to Report 2019 Second Quarter Financial Results on August 6, 2019

DUBLIN , July 23, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced…

Jazz Pharmaceuticals acquires pre-clinical pan-RAF inhibitor program from Redx Pharma

Redx will perform certain pre-clinical activities for the program under a separate collaboration agreement with Jazz. Jazz will be responsible…

Redx Pharmas Lisa Anson discusses potential US$203mln cancer deal

Redx Pharma PLCs (LON:REDX) Lisa Anson speaks to Proactive Londons Andrew Scott after announcing theyve sold one of their cancer…

Redx Pharma sells tumour treatment programme to Jazz Pharmaceuticals

Redx Pharma said it had agreed to sell a programme for the treatment of certain tumours to Jazz Pharmaceuticals for…

Jazz Pharmaceuticals Acquires Pre-clinical Pan-RAF Inhibitor Program from Redx Pharma

DUBLIN , July 10, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced…

Jazz Pharmaceuticals: A Growth Stock Trading At Value Prices

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Jazz Pharmaceuticals Announces Webcast for Sunosi Investor Update

DUBLIN , June 25, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that…

Jazzs (JAZZ) New Sleep Drug Sunosi Gets Schedule IV Status

Jazz Pharmaceuticals (JAZZ) recently approved sleep drug, Sunosi, receives schedule IV designation under controlled substance list from the Drug Enforcement…

Jazz Pharmaceuticals Receives Schedule IV Designation from DEA for Sunosi (solriamfetol)

DUBLIN , June 17, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that…

Should Value Investors Buy Jazz Pharmaceuticals (JAZZ) Stock-

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to…

Is Jazz Pharmaceuticals (JAZZ) Stock Undervalued Right Now-

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to…

Jazz Pharmaceuticals to Present New Data at Upcoming ASCO Annual Meeting and EHA Congress

DUBLIN , May 16, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that…

Jazz Pharmaceuticals (JAZZ) Investor Presentation - Slideshow

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Jazz Pharmaceuticals Data to Showcase Ongoing Sleep Medicine Research at SLEEP 2019

DUBLIN , May 9, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that…

Jazz Pharma (JAZZ) Q1 Earnings and Sales Beat Estimates

Jazz Pharmaceuticals (JAZZ) reports encouraging first-quarter 2019 earnings and revenues and maintains its guidance for 2019....…

Jazz Pharmaceuticals Hits All the Right Notes in Q1

The drugmaker reported strong revenue and earnings growth thanks largely to solid growth for narcolepsy drug Xyrem....…

Jazz Pharmaceuticals (JAZZ) Q1 2019 Earnings Call Transcript

JAZZ earnings call for the period ending March 31, 2019....…

Jazz Pharmaceuticals, Inc. (JAZZ) CEO Bruce Cozadd on Q1 2019 Results - Earnings Call Transcript

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Jazz Pharmaceuticals (JAZZ) Beats Q1 Earnings and Revenue Estimates

Jazz (JAZZ) delivered earnings and revenue surprises of 16.14% and 7.89%, respectively, for the quarter ended March 2019. Do the…

Jazz Pharmaceuticals plc 2019 Q1 - Results - Earnings Call Slides

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Jazz Pharmaceuticals Announces First Quarter 2019 Financial Results

DUBLIN , May 7, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first…

Jazz Pharmaceuticals Announces Participation in Two Upcoming Investor Conferences

DUBLIN , May 6, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced…

Jazz Pharmaceuticals to Report 2019 First Quarter Financial Results on May 7, 2019

Um den gesamten Artikel unter barchart.com zu lesen, klicken Sie bitte auf die Überschrift...…

Jazzs Xyrem Follow-On Drug Succeeds in Phase III Study

Jazz Pharmaceuticals (JAZZ) announced positive top-line data from its phase III study on low sodium formulation of Xyrem, JZP-258....…

Jazz Pharmaceuticals Announces Positive Top-line Results from Phase 3 Study of JZP-258 in Adult Narcolepsy Patients with Cataplexy and Excessive Daytime Sleepiness

DUBLIN , March 26, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive…

UPDATE 2-Jazz Pharmas sleep disorder treatment gets FDA nod

The U.S. Food and Drug Administration approved Jazz Pharmaceuticals Plcs treatment for patients with a form of sleep disorder, the company said…

UPDATE 1-Jazz Pharmas sleep disorder treatment gets FDA nod

The U.S. Food and Drug Administration approved Jazz Pharmaceuticals Plcs treatment for patients with a form of sleep disorder, the company said…

Jazz Pharmas sleep disorder treatment gets FDA nod

The U.S. Food and Drug Administration approved Jazz Pharmaceuticals Plcs treatment for patients with a form of sleep disorder, the company said…

Jazz Pharmaceuticals Announces U.S. FDA Approval of Sunosi (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea

DUBLIN , March 20, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that…